Photo taken from ESMO/LinkedIn
May 23, 2024, 12:46
ESMO – This novel combination therapy holds great promise for BRCA-mutated metastatic Breast Cancers
ESMO shared a post on LinkedIn:
“ESMOBreast24: phase 2 data on combining olaparib, durvalumab, and fulvestrant for ER+/HER2- metastatic Breast Cancer with germline BRCA1/2 or other DNA repair mutations.
Key Results:
At median follow-up of 24.6 months, 66% PFS rate at 24 weeks overall and 76% in gBRCA1/2m carriers
Overall, median PFS of 9.3 months, ORR 41%, median OS 30 months
Median PFS of 12.6 months in gBRCA1/2m carriers
The triplet showed a synergic effect, with higher benefits in BRCA1/2 carriers.
This novel combination of PARP inhibition, immunotherapy, and endocrine therapy holds great promise, especially for BRCA-mutated metastatic Breast Cancers. ”
Read further.
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19